Selpercatinib (Retevmo), a drug targeted precisely against cancers driven by mutations or alterations in the gene RET, was effective in a clinical trial at shrinking tumors in patients with medullary thyroid cancer, with ...
Aug 26, 2020
0
36
A protein highly expressed in lung cancer cells drives resistance to targeted therapies, report researchers at the Medical University of South Carolina in the Journal of Thoracic and Cardiovascular Surgery. In preclinical ...
Aug 24, 2020
0
3
Dogs may hold the key to uncovering novel cancer therapy targets and treatments that will benefit domestic animals and their owners, as well as human cancer patients.
Aug 17, 2020
0
9
Many types of human cancers exhibit changes in kinase and phosphatase balances. Drugs that inhibit kinase activity have shown success in the clinic as cancer therapeutics, but the phosphatases still remain a largely underexploited ...
Aug 12, 2020
0
157
Tyrosine kinases are protein enzymes that have many functions within cells, including cell signaling, growth, and division. Sometimes these enzymes can be overactive, which helps cancer cells survive and multiply. A tyrosine ...
Jul 31, 2020
0
72
Researchers at The Ohio State University Comprehensive Cancer Center—Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC—James) and The Ohio State University Wexner Medical Center are conducting ...
Jul 29, 2020
0
3
Precision medicine in cancer treatment uses genetic changes in the cancer cells to select the best therapies for individual patients.
Jul 28, 2020
0
127
An international team of researchers has analyzed how SARS-CoV-2, the virus that causes COVID-19, hijacks the proteins in its target cells. The research, published in the journal Cell, shows how the virus shifts the cell's ...
Jun 29, 2020
0
820
Researchers with SAHMRI's Precision Medicine Theme have found a key to better identifying which chronic myeloid leukaemia (CML) patients can stop taking their medication and remain in treatment free remission (TFR).
May 1, 2020
0
1
A one-year follow-up study led by The University of Texas MD Anderson Cancer Center revealed a majority of patients with mantle cell lymphoma resistant to prior therapies may benefit from treatment with CD19-targeting chimeric ...
Apr 1, 2020
0
13
